Moreover, a Phase I clinical trial testing a T4-CAR T cell approach targeting the ErbB family demonstrated safe intratumoral administration and stable disease with few adverse effects [9], and additional clinical trials in HNSCC using CAR-T cells targeting MUC1, PD-1, EpCAM and EBV are currently recruiting (NCT05239143, NCT05117138, NCT03740256, NCT05639972, NCT02915445, NCT04847466). Here, EPCAM is linked to head and neck squamous cell carcinoma.